-
Fosun Pharma’s Generic Remodulin Gains NMPA Approval for Pulmonary Arterial Hypertension
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its generic version of Remodulin (treprostinil) has been approved by the National Medical Products Administration (NMPA) for the treatment of pulmonary arterial hypertension (PAH). The drug is marketed to alleviate symptoms caused by exercise. Understanding PAH and…
-
RemeGen Gains NMPA Approval for Phase I/IIa Study of RC88 with Junshi Bio’s PD-1 Inhibitor
•
China-based pharmaceutical firm RemeGen (HKG: 9995) has received approval from the National Medical Products Administration (NMPA) to conduct an open, multi-center Phase I/IIa study. The study will assess the safety, tolerability, pharmacokinetics, and efficacy of RC88 combined with Junshi Bio’s (HKG: 1877, SHA: 688180) programmed death-1 (PD-1) inhibitor, Tuoyi (toripalimab),…
-
Triastek Partners with Boehringer Ingelheim to Advance 3D Printed Drug Dosage Forms
•
China-based Triastek Inc., a leading pharmaceutical-focused 3D printing company, has entered into a partnership with German pharmaceutical giant Boehringer Ingelheim. The collaboration aims to explore the application of 3D printing in the development of new chemical entity (NCE) drug dosage forms, although no financial details were disclosed. Triastek’s Technology and…
-
ImmuneOnco Gains NMPA Approval for Phase Ib/II Study of IMM27M in Advanced Tumors
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase Ib/II clinical study for its IMM27M. This ADCC-enhanced CTLA-4 monoclonal antibody (mAb) will be combined with the programmed death-1 (PD-1) inhibitor tislelizumab for the treatment…
-
ArkBio and Calibr Renew Collaboration to Develop First-in-Class Respiratory Drug AK0705
•
Shanghai Ark Biopharmaceutical Co., Ltd announced that it has renewed its co-development collaboration with Calibr, a division of Scripps Research, to develop AK0705, a potential first-in-class drug targeting an enzyme that plays a crucial role in respiratory inflammation. The drug is intended to treat a broad spectrum of respiratory diseases,…
-
Agena Bioscience’s CYP2C19 Genotyping Kit Gains NMPA Approval for Cardiovascular Applications
•
Shanghai-based Agena Bioscience announced that its human CYP2C19 genotyping test kit, co-developed with Simcere Pharmaceutical Group’s subsidiary Simcere Diagnostics, has been approved by the National Medical Products Administration (NMPA) as a Category III product. The kit is designed for the qualitative detection of CYP2C19 gene polymorphism in peripheral blood samples…
-
Ping An Life Insurance Reports Steady Profit Growth and Expands Managed Care Services
•
Ping An Life Insurance Company of China Ltd released its 2022 financial report, recording RMB 148.365 billion (USD 21.485 billion) in operating profits, up 0.3% year-on-year (YOY). The company also reported RMB 107.432 billion (USD 15.55 billion) in net profits and RMB 83.774 billion (USD 12.13 billion) in net profits…
-
Akeso Biopharma Reports 422% Increase in Product Sales, Boosted by Cadonilimab and Penpulimab
•
China-based Akeso Biopharma (HKG: 9926) released its 2022 financial report, highlighting significant growth in product sales. The company reported RMB 1.104 billion (USD 159.97 million) in product sales, representing a 422% year-on-year (YOY) increase. Product Sales and Market ApprovalsThe innovative bispecific antibody cadonilimab (AK104), targeting programmed death-1 (PD-1) and cytotoxic…
